Applying the same principle, targeting the phase separation of BRD4 with the BRD4 degrader ARV-825 (Figure 3D), particularly focusing on its short isoform (BRD4S), known for forming distinct condensates in chromatin within liver cancer cells, has proven to be an efficacious approach for targeting HCC (Shi et al., 2023). This evidence concerns the gene BRD4 and hepatocellular carcinoma.